vTv Therapeutics Inc.

Last updated September 27, 2026

Favorite this organization

Organization details

Legal name: vTv Therapeutics Inc.
Ownership: Public
Status: Active
Sector (GICS): Health Care
SIC code: 2834 — Pharmaceutical Preparations
Jurisdiction of incorporation: Delaware
Headquarters city: High Point
Headquarters state / province: North Carolina
Headquarters country: United States
Fiscal year end: December
Ticker symbol: VTVT
Primary stock exchange: Nasdaq

Identifiers

SEC CIK: 0001641489
EIN: 47-3916571

Board of directors

Follow this board

Anne M. Phillips · Director
Since 2024
Chandresh Harjivan · Director
Since 2023
Daniel K. Spiegelman · Director Overboarded
Since 2024
Fahed Al-Marzooqi · Director
Since 2023
Felix Baker · Director Overboarded
Since 2024
Hersh Kozlov · Director
Since 2023
Howard L. Weiner · Director
Since 2023
John A. Fry · Director
Since 2023
Jonathan Isaacsohn · Director
Since 2023
Julian Baker · Director Overboarded
Since 2024
Keith R. Harris · Director
Since 2023
Paul J. Sekhri · Director · Pres, CEO and Exec Chairperson
Since 2024
Raymond Cheong · Director
Since 2024
Srinivas Akkaraju · Director Overboarded
Since 2024

Chief executives

Paul J. Sekhri · President and CEO

Dates unknown

Director election results

Annual meeting of June 26, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.

Fahed Al-Marzooqi

90.1%

Board connections

10 of this board's directors also sit on 30 other boards. 27 are in the same sector.

Shared director Other board Same sector +14 more in the list below

Madrigal Pharmaceuticals Inc. Same sector
via Felix Baker, Julian Baker and Raymond Cheong
ACADIA Pharmaceuticals Inc. Same sector
via Felix Baker and Julian Baker
BeOne Medicines Ltd. Same sector
via Felix Baker and Julian Baker
Bicycle Therapeutics plc Same sector
via Felix Baker and Julian Baker
DBV Technologies S.A. Same sector
via Felix Baker and Julian Baker
Denali Therapeutics Inc. Same sector
via Felix Baker and Julian Baker
Immunocore Holdings plc Same sector
via Felix Baker and Julian Baker
Incyte Corp. Same sector
via Felix Baker and Julian Baker
Kiniksa Pharmaceuticals International plc Same sector
via Felix Baker and Julian Baker
Kodiak Sciences Inc Same sector
via Felix Baker and Julian Baker
Kymera Therapeutics Inc. Same sector
via Felix Baker and Julian Baker
Neurogene Inc. Same sector
via Felix Baker and Julian Baker
Prelude Therapeutics Incorporated Same sector
via Felix Baker and Julian Baker
Replimune Group Inc. Same sector
via Felix Baker and Julian Baker
TScan Therapeutics Inc. Same sector
via Felix Baker and Julian Baker
Alumis Inc. Same sector
via Srinivas Akkaraju
Apnimed Inc. Same sector
via Paul J. Sekhri
BTC Development Corp.
via Hersh Kozlov
Community Health Systems Inc. Same sector
via John A. Fry
Kalaris Therapeutics Inc. Same sector
via Srinivas Akkaraju
Kyverna Therapeutics Inc. Same sector
via Daniel K. Spiegelman
Maze Therapeutics Inc. Same sector
via Daniel K. Spiegelman
MeiraGTx Holdings plc Same sector
via Keith R. Harris
Mineralys Therapeutics Inc. Same sector
via Srinivas Akkaraju
Myriad Genetics Inc. Same sector
via Daniel K. Spiegelman
Sagimet Biosciences Inc. Same sector
via Anne M. Phillips
Scholar Rock Holding Corporation Same sector
via Srinivas Akkaraju
Spruce Biosciences Inc. Same sector
via Daniel K. Spiegelman
The Bancorp Inc
via Hersh Kozlov
Veeva Systems Inc.
via Paul J. Sekhri

Insider trades

All notable trades →

From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.

Bought, last 12 months: $0; 0 purchases by 0 insiders
Sold, last 12 months: $0; 0 sales by 0 insiders

Date	Insider	Transaction	Shares	Price	Value
Sep 22, 2025	Srinivas Akkaraju Director	Grant or award	+106,000	$15.27	$1,618,620
Sep 3, 2025	Julian Baker Director	Grant or award	+4,308	—	—
Sep 3, 2025	Julian Baker Director	Grant or award	+46,692	—	—
Nov 18, 2024	Paul J. Sekhri Director, Officer (Pres, CEO and Exec Chairperson)	Open-market purchase	+1,844	$16.96	$31,274
Nov 15, 2024	Paul J. Sekhri Director, Officer (Pres, CEO and Exec Chairperson)	Open-market purchase	+1,378	$16.35	$22,530
Nov 15, 2024	Paul J. Sekhri Director, Officer (Pres, CEO and Exec Chairperson)	Open-market purchase	+1,778	$16.88	$30,013
Mar 5, 2024	667, L.P. Director	Sold back to the company	−4,776	—	—
Mar 5, 2024	Samsara BioCapital, L.P. 10% owner	Other	−58,836	—	—
Mar 5, 2024	Srinivas Akkaraju Director, 10% owner	Sold back to the company	−58,836	—	—
Mar 5, 2024	667, L.P. Director	Sold back to the company	−52,881	—	—
Feb 27, 2024	Srinivas Akkaraju Director, 10% owner	Grant or award	+224,732	$11.81	$2,654,085

Peers

Compare boards

Organizations in the same sector, closest in location and size first.

3M Company NYSE: MMM · ST Paul, United States Organization ABVC BioPharma Inc. Nasdaq: ABVC · Fremont, United States Organization ACADIA Pharmaceuticals Inc. Nasdaq: ACAD · SAN Diego, United States Organization ADMA Biologics Inc Nasdaq: ADMA · Ramsey, United States Organization

Questions about vTv Therapeutics Inc.

Who is the CEO of vTv Therapeutics Inc.?

Paul J. Sekhri is vTv Therapeutics Inc.'s President and CEO.

How many directors are on vTv Therapeutics Inc.'s board?

vTv Therapeutics Inc.'s board has 14 directors: Anne M. Phillips, Chandresh Harjivan, Daniel K. Spiegelman, Fahed Al-Marzooqi, Felix Baker, Hersh Kozlov, Howard L. Weiner, John A. Fry, Jonathan Isaacsohn, Julian Baker and 4 others.

How is vTv Therapeutics Inc. connected to…? → Spot something wrong? Report a correction

Embed this board on your site

Paste this where the board should appear. It always shows the current directors and links back here.

<div data-bod-board="vtv-therapeutics-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>

Reviews (0)

No reviews yet. Be the first to write one.